Annual report pursuant to Section 13 and 15(d)

Intangible Assets

v3.24.1
Intangible Assets
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

7. Intangible Assets

 

The net carrying value of the identifiable intangible assets from all acquisitions within continuing operations as of December 31, 2023 and December 31, 2022 are as follows:

 

         

As of

December 31, 2023

    

As of

December 31, 2022

  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
                   
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       6,682       6,682  
                         
CLIA Lab     2.3       609       609  
                         
Total           $ 31,951     $ 31,951  
                         
Accumulated Amortization             (31,951 )     (31,090 )
                         
Net Carrying Value           $ -     $ 861  

 

Amortization expense from continuing operations was approximately $0.9 million and $1.3 million for the years ended December 31, 2023 and 2022, respectively. The Company’s identifiable intangible assets were fully amortized as of December 31, 2023.